FDA 483 - Goodwin Biotechnology, Inc. - May 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Goodwin Biotechnology Inc. in Plantation, FL, was cited for significant deficiencies across its drug substance intermediate manufacturing operations. The inspection revealed widespread issues including inadequate contamination controls, unsanitary facility conditions, compromised data integrity in computerized systems and production records, and a lack of proper laboratory and quality unit oversight. These findings indicate a systemic failure to adhere to cGMP requirements.
ID · 70d41cf2-798a-40f1-b25e-15fbf40f6188